Clinical Trials Directory

Trials / Completed

CompletedNCT03990701

Primary Aldosteronism and Surgically Curable Forms in Hypertension Patients Using 11C-Metomidate

Status
Completed
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
25 (actual)
Sponsor
Changi General Hospital · Academic / Other
Sex
All
Age
21 Years – 70 Years
Healthy volunteers
Not accepted

Summary

10% of patients with hypertension potentially have the treatable condition - primary aldosteronism. Primary aldosteronism (PA) is caused by either bilateral adrenal disease (\~40%), managed with lifelong medications; or unilateral disease (\~60%), cured with laparoscopic surgery (adrenalectomy). Unfortunately, many patients with curable hypertension remain undiagnosed and consequently develop cardiac disease and strokes. The difficulty with identifying curable unilateral disease is due to adrenal vein sampling (AVS): an invasive, and technically-difficult procedure, with inconclusive results in 50% of patients. An alternative novel imaging, 11C-metomidate Positron emission tomography-computed tomography (PET-CT), can detect adrenal tumors, and concurrently confirm their over-activity. It is non-invasive, non-operator-dependent, and can identify more patients with curable hypertension. Investigators hypothesize that 11C-metomidate PET-CT can accurately identify patients with surgically-curable unilateral adrenal disease among hypertensive Asians with primary aldosteronism.

Detailed description

25 patients with confirmed PA who are keen for a surgical cure if unilateral PA is confirmed, will undergo conventional tests, CT, AVS, as well as 11C-metomidate PET/CT. Results will be reviewed and discussed at a multidisciplinary meeting, and patients with unilateral PA will be offered surgery. Patients will be reviewed 6 months post surgery to assess for cure of PA.

Conditions

Interventions

TypeNameDescription
COMBINATION_PRODUCT11C-Metomidate PET/CT Scan11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre

Timeline

Start date
2018-05-21
Primary completion
2021-03-30
Completion
2021-03-30
First posted
2019-06-19
Last updated
2021-06-01

Locations

1 site across 1 country: Singapore

Source: ClinicalTrials.gov record NCT03990701. Inclusion in this directory is not an endorsement.